• PB2126: R-CPOP as first line t...
  • *Holdings*

*Result*: PB2126: R-CPOP as first line treatment for DLBCL patients with significant reduced LVEF or high risk of anthracycline induced cardiotoxicity

*Title*:
PB2126: R-CPOP as first line treatment for DLBCL patients with significant reduced LVEF or high risk of anthracycline induced cardiotoxicity
*Author/editor-in-chief*:
Lorenz, Katrin (Verfasser) ; Strüßmann, Tim (Verfasser) ; Trepel, Martin (Verfasser) ; Illerhaus, Gerald (Verfasser) ; Pelz, Henning (Verfasser); Scholz, Catherine (Verfasser); Duyster, Justus (Verfasser) ; Marks, Reinhard (Verfasser) 
*Publication*:
Freiburg : Universität, 2024
*Physical description scale*:
1 Online-Ressource
*Format*:
*eBook*
*Language*:
*eng*
*Notes*:
ISSN: 2572-9241
*DOI*:
10.1097/01.hs9.0000851336.89795.74

*Additional information*

*Additional functions*